A 52-year-old man with COPD is prescribed both ipratropium and albuterol inhalers. Which single feature best distinguishes the mechanism of action of ipratropium from albuterol in producing bronchodilation?

Explanation

## Mechanistic Distinction: Anticholinergic vs. Beta-2 Agonist Bronchodilation ### Receptor-Level Mechanism **Key Point:** Ipratropium and albuterol achieve bronchodilation through fundamentally different receptor pathways — anticholinergic blockade versus adrenergic activation. | Parameter | Ipratropium | Albuterol | |-----------|-------------|----------| | **Drug class** | Anticholinergic (muscarinic antagonist) | Beta-2 agonist | | **Target receptor** | M3 muscarinic on airway smooth muscle | Beta-2 adrenergic on airway smooth muscle | | **Mechanism** | Blocks acetylcholine → ↓ contraction | Activates cAMP pathway → ↑ relaxation | | **Onset** | 30–60 minutes | 5–15 minutes | | **Duration** | 6–8 hours | 4–6 hours | | **Reversibility** | Reversible antagonism | Reversible agonism | ### Pathophysiology of Action **Clinical Pearl:** In COPD, acetylcholine-mediated bronchoconstriction is a major component of airway obstruction. Ipratropium blocks this parasympathetic tone at the M3 receptor, while albuterol independently activates smooth muscle relaxation via the sympathetic pathway. They work on **different receptor systems** — this is the core distinction. **High-Yield:** The combination of ipratropium + albuterol in COPD is synergistic because they target non-overlapping mechanisms: - Ipratropium removes the braking force (parasympathetic tone) - Albuterol adds the accelerating force (sympathetic stimulation) ### Mnemonic **IPRA-CHOL:** **I**pratropium = **A**cetylcholine **BLOCK** (anticholinergic) **ALBU-ADREN:** **A**lbuterol = **A**drenergic **ACTIVATION** [cite:Harrison 21e Ch 254]